WAYLIVRA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, UK.

Active ingredients

The drug WAYLIVRA contains one active pharmaceutical ingredient (API):

1	Volanesorsen UNII 6JON30SLDT - VOLANESORSEN SODIUM
	Volanesorsen is an antisense oligonucleotide designed to inhibit the formation of apoC-III, a protein that is recognised to regulate both triglyceride metabolism and hepatic clearance of chylomicrons and other triglyceride-rich lipoproteins.
	Read more about Volanesorsen

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
WAYLIVRA Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C10AX	Other lipid modifying agents	C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain
Discover more medicines within C10AX

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1795956, 1795967
FR	Base de données publique des médicaments	65766872
GB	Medicines & Healthcare Products Regulatory Agency	376465
IT	Agenzia del Farmaco	047941012, 047941024
LT	Valstybinė vaistų kontrolės tarnyba	1087707, 1087708
PL	Rejestru Produktów Leczniczych	100421193
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67657001, W67657002